Veralto delivers solid growth but at demanding multiples. Find out why VLTO stock is still too rich for a 'buy' despite a ...

Danaher (NYSE:DHR) shares rose more than 2% intra-day today after it received an upgrade from Hold to Buy from Stifel ...

Fintel reports that on March 14, 2025, Stifel upgraded their outlook for Danaher (NYSE:DHR) from Hold to Buy. Analyst Price ...

Following the rerating, Danaher shares seem to have found their footing, with downward [earnings] estimate revisions ...

As previously reported, Stifel analyst Daniel Arias upgraded Danaher (DHR) to Buy from Hold with an unchanged price target of $260, telling ...

Stifel upgraded Danaher (DHR) to Buy from Hold with a $260 price target Light Up your Portfolio with Spark:Easily identify stocks' risks and ...

The Rising Need for Efficient and Effective Drug Discoveries Worldwide is Expected to Create Lucrative Growth Opportunities in the Market.

AbbVie, CervoMed, Thermo Fisher Scientific, Danaher, Vertex Pharmaceuticals, Cencora, and Cognizant Technology Solutions are the seven Biotech stocks to watch today, according to MarketBeat’s stock ...

Banco Santander increased its stake in Danaher by 56.2%, now holding 8,757 shares worth $2.01 million. Several other ...

DCF analysis, a reliable and data-driven approach to estimating its intrinsic value. Instead of using future free cash flow ...

AbbVie, Danaher, and Thermo Fisher Scientific are the three Biotech stocks to watch today, according to MarketBeat’s stock ...

Why Is Danaher Corporation’s Stock Showing Market Fluctuations?